{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T07:29:11Z","timestamp":1785569351980,"version":"3.56.0"},"reference-count":12,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2022,2,17]],"date-time":"2022-02-17T00:00:00Z","timestamp":1645056000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Hematological Oncology"],"published-print":{"date-parts":[[2022,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    COVID\u201019 significantly impairs survival rates among hematological patients when compared to the general population. Our prospective multicentre project analyzed early administration of anti\u2010SARS\u2010CoV\u20102 spike protein neutralizing monoclonal antibodies (NmAbs) \u2013 bamlanivimab (72%) and casirivimab\/imdevimab (28%) \u2013 efficacy among hematological patients with early\u2010stage COVID\u201019. Mortality rate was compared to a control cohort of 575 SARS\u2010CoV\u20102 positive hematological patients untreated with any specific anti\u2010COVID\u201019 therapy. 88 hematological patients with lymphomas, acute leukemias, and myeloma as their most frequent underlying diagnoses (72%) were evaluated with a 97\u00a0days median follow\u2010up after NmAb administration. One third of patients (32%) were treated with an anti\u2010CD20 monoclonal antibody before COVID\u201019 diagnosis. Median time between first COVID\u201019 symptom and NmAb administration was 2\u00a0days. When administering NmAb, 29%, 57%, 11%, 2%, and 1% of our patients had asymptomatic, mild, moderate, severe, and critical degrees of COVID\u201019, respectively. 80% of baseline asymptomatic patients remained asymptomatic following NmAb administration. Median duration of COVID\u201019 symptoms after NmAb administration was 2.5\u00a0days. Progression to severe\/critical COVID\u201019 occurred among a total of 17% (15\/88) of our cases and numerically higher with bamlanivimab versus casirivimab\/imdevimab (21% vs. 8%;\n                    <jats:italic>p<\/jats:italic>\n                    \u00a0=\u00a00.215), and myelomas (29%), lymphomas (17%) and acute leukemias (18%), respectively. During final follow\u2010up, nine deaths (10%) were recorded \u2010 all after bamlanivimab (\n                    <jats:italic>p<\/jats:italic>\n                    \u00a0=\u00a00.056) with 8% attributed to COVID\u201019. Regarding \u201cremdesivir\/convalescent plasma na\u00efve\u201d patients, COVID\u201019 mortality rates were significantly lower in our NmAbs treated cohort compared to the control cohort of untreated SARS\u2010CoV\u20102 positive hematological patients (6% vs. 16%,\n                    <jats:italic>p<\/jats:italic>\n                    \u00a0=\u00a00.020), respectively. Our study validated the safety and efficacy of NmAbs early use among hematological patients with newly diagnosed early\u2010stage COVID\u201019 in terms of alleviating infection course and decreasing mortality. Results confirmed a more positive effect of a casirivimab\/imdevimab combination versus bamlanivimab monotherapy.\n                  <\/jats:p>","DOI":"10.1002\/hon.2974","type":"journal-article","created":{"date-parts":[[2022,2,4]],"date-time":"2022-02-04T14:38:30Z","timestamp":1643985510000},"page":"280-286","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["Successful early use of anti\u2010SARS\u2010CoV\u20102 monoclonal neutralizing antibodies in SARS\u2010CoV\u20102 infected hematological patients \u2013 A Czech multicenter experience"],"prefix":"10.1002","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6460-2471","authenticated-orcid":false,"given":"Barbora","family":"Weinbergerov\u00e1","sequence":"first","affiliation":[{"name":"Department of Internal Medicine \u2013 Hematology and Oncology Masaryk University  Brno Czech Republic"},{"name":"Department of Internal Medicine \u2013 Hematology and Oncology University Hospital Brno  Brno Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivo","family":"Demel","sequence":"additional","affiliation":[{"name":"Department of Haemato\u2010oncology University Hospital Ostrava  Ostrava Czech Republic"},{"name":"Department of Haemato\u2010oncology Faculty of Medicine, University of Ostrava  Ostrava Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"V\u00ed\u0161ek","sequence":"additional","affiliation":[{"name":"4th Department of Internal Medicine\u2010Hematology University Hospital Hradec Kralove  Hradec Kralove Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"V\u00e1lka","sequence":"additional","affiliation":[{"name":"Institute of Hematology and Blood Transfusion  Prague Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"\u010cer\u0148an","sequence":"additional","affiliation":[{"name":"Department of Hemato\u2010Oncology Faculty of Medicine and Dentistry Palack\u00fd University Olomouc and University Hospital Olomouc  Olomouc Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pavel","family":"Jindra","sequence":"additional","affiliation":[{"name":"Department of Haematology and Oncology University Hospital Pilsen  Pilsen Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Nov\u00e1k","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine and Haematology University Hospital Kr\u00e1lovsk\u00e9 Vinohrady and Third Faculty of Medicine Charles University  Prague Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luk\u00e1\u0161","family":"Stejskal","sequence":"additional","affiliation":[{"name":"Department of Hematology Silesian Hospital in Opava  Opava Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fl\u00f3ra","family":"Kov\u00e1csov\u00e1","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine \u2013 Hematology and Oncology Masaryk University  Brno Czech Republic"},{"name":"Department of Internal Medicine \u2013 Hematology and Oncology University Hospital Brno  Brno Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom\u00e1\u0161","family":"Kabut","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine \u2013 Hematology and Oncology Masaryk University  Brno Czech Republic"},{"name":"Department of Internal Medicine \u2013 Hematology and Oncology University Hospital Brno  Brno Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom\u00e1\u0161","family":"Szotkowski","sequence":"additional","affiliation":[{"name":"Department of Hemato\u2010Oncology Faculty of Medicine and Dentistry Palack\u00fd University Olomouc and University Hospital Olomouc  Olomouc Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roman","family":"H\u00e1jek","sequence":"additional","affiliation":[{"name":"Department of Haemato\u2010oncology University Hospital Ostrava  Ostrava Czech Republic"},{"name":"Department of Haemato\u2010oncology Faculty of Medicine, University of Ostrava  Ostrava Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pavel","family":"\u017d\u00e1k","sequence":"additional","affiliation":[{"name":"4th Department of Internal Medicine\u2010Hematology University Hospital Hradec Kralove  Hradec Kralove Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petr","family":"Cetkovsk\u00fd","sequence":"additional","affiliation":[{"name":"Institute of Hematology and Blood Transfusion  Prague Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zden\u011bk","family":"Kr\u00e1l","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine \u2013 Hematology and Oncology Masaryk University  Brno Czech Republic"},{"name":"Department of Internal Medicine \u2013 Hematology and Oncology University Hospital Brno  Brno Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji\u0159\u00ed","family":"Mayer","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine \u2013 Hematology and Oncology Masaryk University  Brno Czech Republic"},{"name":"Department of Internal Medicine \u2013 Hematology and Oncology University Hospital Brno  Brno Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2022,2,17]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2029849"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2035002"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI151697"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciab579"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020008824"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-021-01177-0"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/ctr.14245"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1097\/TP.0000000000003737"},{"key":"e_1_2_10_10_1","first-page":"jiab406","article-title":"SARS\u2010CoV\u20102 specific monoclonal antibody for the treatment of mild\u2010to\u2010moderate COVID\u201019 in cancer patients: a single\u2010center experience","author":"Puing AG","year":"2021","journal-title":"J Infect Dis"},{"key":"e_1_2_10_11_1","article-title":"Monoclonal antibodies for the treatment of COVID\u201019 in a patient with high\u2010risk acute leukaemia","volume":"196","author":"Saultier P","year":"2021","journal-title":"Br J Haematol"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMcp2009249"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-021-03720-y"}],"container-title":["Hematological Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/hon.2974","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/hon.2974","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/hon.2974","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,25]],"date-time":"2023-08-25T14:52:22Z","timestamp":1692975142000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/hon.2974"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,17]]},"references-count":12,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,4]]}},"alternative-id":["10.1002\/hon.2974"],"URL":"https:\/\/doi.org\/10.1002\/hon.2974","archive":["Portico"],"relation":{"has-review":[{"id-type":"doi","id":"10.1002\/HON.2974\/v1\/review2","asserted-by":"object"},{"id-type":"doi","id":"10.1002\/HON.2974\/v1\/review1","asserted-by":"object"},{"id-type":"doi","id":"10.1002\/HON.2974\/v2\/review1","asserted-by":"object"},{"id-type":"doi","id":"10.1002\/HON.2974\/v2\/decision1","asserted-by":"object"},{"id-type":"doi","id":"10.1002\/HON.2974\/v1\/decision1","asserted-by":"object"}]},"ISSN":["0278-0232","1099-1069"],"issn-type":[{"value":"0278-0232","type":"print"},{"value":"1099-1069","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,17]]},"assertion":[{"value":"2022-02-17","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}